Study Details
A Study Testing Two Immunotherapy Drugs for Children and Young Adults with Relapsed Leukemia
(IRB#: IRB_00139680)
This study is designed to find better ways to treat children and young adults (ages 1 to under 31) who have a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL) that has come back after initial treatment. The study is testing whether adding a new medicine called nivolumab to an existing treatment called blinatumomab will help improve outcomes.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Unpaid
Who can participate?
Gender: All genders
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Participants must be between 1 year and less than 31 years old at the time of enrollment.
- Participants must have a diagnosis of first relapse of B-cell acute lymphoblastic leukemia (B-ALL) that is positive for the CD19 marker. This relapse can be in the bone marrow, central nervous system (brain or spinal fluid), testes, or a combination of these sites.
- Participants must have recovered from any side effects of previous cancer treatments, including chemotherapy, immunotherapy, or radiation therapy. Those who have had a prior stem cell or bone marrow transplant are not eligible.
- Participants must have adequate kidney, heart, and lung function based on medical tests to safely receive the study treatments.
Exclusion Criteria
- Cannot join if diagnosed with a different type of leukemia, such as Burkitt leukemia or mixed phenotype acute leukemia.
- Cannot join if currently experiencing a serious infection or fever within the last 48 hours.
- Cannot join if diagnosed with certain rare genetic conditions, such as Fanconi anemia or Bloom syndrome.
Will I be paid for my time?
No
IRB#: IRB_00139680
PI: Luke Maese
Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
Approval Date: 2021-02-10 20:57:00
Study Categories: Cancer Studies
Specialties: Pediatric Hematology & Oncology
I am Interested